Modulation of Na(+), K(+)-ATPase activity by acute and chronic opiates has been established for many years. However, the effects of digoxin, a putative inhibitor of Na(+), K(+)-ATPase, on naloxone-precipitated morphine withdrawal syndrome are unknown. In the present study, a digoxin dose-response curve was conducted to observe the effects on naloxone-precipitated withdrawal and locomotor activity in mice. Higher doses of digoxin (1.0 and 2.5 mg/kg) inhibited locomotor activity and naloxone-precipitated withdrawal jumping and weight loss, while lower doses of digoxin (0.1 and 0.25 mg/kg) inhibited withdrawal weight loss precipitated by naloxone without affecting locomotor activity and naloxone-precipitated withdrawal jumping. To explore the possible mechanisms underlying this behavior, another Na(+), K(+)-ATPase inhibitor ouabain, which does not cross the blood brain barrier, and another cardiotonic drug milrinone, a non-inhibitor of Na(+), K(+)-ATPase, were also included in the present study. Both milrinone and ouabain inhibited, in a dose-dependent manner, naloxone-precipitated weight loss while neither affected naloxone-precipitated withdrawal jumping nor locomotor activity in mice. These results indicate that both the cardiotonic effects and central inhibition of Na(+), K(+)-ATPase contribute to the inhibitory effects of digoxin on morphine withdrawal syndrome in mice.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ejphar.2012.08.004 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Synaptic Structure and Transcriptomic Profiling of Reward and Sensory Brain Areas in Male Mice of Fentanyl Addiction.
Subst Abuse Rehabil
December 2024
The Joint Innovation Center for Health & Medicine, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People's Hospital, Quzhou, 324000, People's Republic of China.
Background: Opioid-based medications are powerful analgesics commonly prescribed for pain management, but they are also highly addictive. The over-prescription of opioids analgesics has triggered current opioid crisis, which now has expanded to heroin and illicit synthetic opioids like fentanyl and its analogues. The side effects of fentanyl abuse have been well recognized, yet the underlying molecular adaptations across brain regions upon fentanyl exposure remain elusive.
View Article and Find Full Text PDFRegion-specific neuroadaptations of CRF1 and CRF2 expression following heroin exposure in female rats.
Pharmacol Biochem Behav
December 2024
Department of Psychological and Brain Sciences, Colgate University, Hamilton, NY, USA. Electronic address:
Article Synopsis
- - Stress increases the risk of addiction and the role of corticotropin releasing factor (CRF) is critical, but how CRF1 and CRF2 receptors impact heroin use is not fully understood.
- - In a study involving female rats, blocking CRF1 and CRF2 receptors reduced heroin self-administration, highlighting their importance in drug-seeking behavior.
- - Chronic heroin exposure caused specific changes in CRF receptor expression in different brain regions, suggesting that these neuroadaptations may contribute to ongoing drug use and withdrawal symptoms.
Fentanyl exposure alters rat CB1 receptor expression in the insula, nucleus accumbens and substantia nigra.
Neurosci Lett
January 2025
Department of Psychological and Brain Sciences, Colgate University, Hamilton, NY, USA. Electronic address:
Prolonged periods of opioid use have been shown to cause neuroadaptations in the brain's reward circuitry, contributing to addictive behaviors and drug dependence. Recently, considerable focus has been placed on the role of the endocannabinoid system (ECS) and its CB receptors in opioid-driven behaviors. However, opioid-induced neuroadaptations to the ECS remain understudied.
View Article and Find Full Text PDFPreclinical evaluation of abuse potential of the peripherally-restricted kappa opioid receptor agonist HSK21542.
Regul Toxicol Pharmacol
December 2024
Saifu Laboratories Co., Ltd., Beijing, China; SAFE Medical Technology Co., Ltd., Hebei, China. Electronic address:
HSK21542 is a peripherally-restricted kappa opioid receptor (KOR) agonist developed for pain treatment. Because of the CNS pharmacological concern of opioid receptor activation, such as physical dependence and addiction potential, an assessment of abuse potential of HSK21542 was required prior to marketing approval. The preclinical abuse potential assessments for HSK21542 included the following studies: 1) intravenous self-administration study to explore the relative reinforcing efficacy in rats self-administering remifentanil; 2) rat drug discrimination study to examine the pharmacological similarity of the interoceptive or subjective effects of HSK21542 in rats discriminating pentazocine; 3) rat conditioned place preference (CPP) paradigm to test the rewarding effects; 4) rat natural physical dependence-spontaneous withdrawal study in rats chronically treated with HSK21542; 5) naloxone-precipitated withdrawal assay following chronic HSK21542 exposure to evaluate its physical dependence potential.
View Article and Find Full Text PDFYTHDF1 in periaqueductal gray inhibitory neurons contributes to morphine withdrawal responses in mice.
BMC Med
September 2024
Department of Anesthesiology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, P. R. China.
Background: Physical symptoms and aversion induced by opioid withdrawal strongly affect the management of opioid addiction. YTH N6-methyladenosine (mA) RNA binding protein 1 (YTHDF1), an mA-binding protein, from the periaqueductal gray (PAG) reportedly contributes to morphine tolerance and hyperalgesia. However, the role of YTHDF1 in morphine withdrawal remains unclear.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!